Nugent Shannon, Latour Emile, Lim Jeong, Shannon Jackilen, Morasco Benjamin J
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Department of Psychiatry, Oregon Health & Science University; Portland, OR, USA.
Integr Med Rep. 2024 Jul 22;3(1):81-91. doi: 10.1089/imr.2024.0001. eCollection 2024.
Cannabis use for symptom management among individuals with cancer is increasingly common.
We sought to describe the (1) prevalence and characteristics of cannabis use, (2) perceived therapeutic benefits of cannabis use, and (3) examine how use of cannabis was associated with self-reported pain, mood, and general health outcomes in a representative sample of patients treated at a National Cancer Institute (NCI)-designated Oregon Health and Science University Knight Cancer Institute.
We conducted a population-based, cross-sectional survey developed in conjunction with 11 other NCI-designated cancer centers and distributed to eligible individuals. The survey inquired about characteristics of cannabis use, perception of therapeutic benefits, pain, mood, and general health. Responses were population weighted. We examined the association of cannabis use with self-reported pain, mood, and general health using logistic regression controlling for relevant sociodemographic and clinical characteristics.
A total of 523 individuals were included in our analytic sample. A total of 54% endorsed using cannabis at any time since their cancer diagnosis and 42% endorsed using cannabis during active treatment. The most commonly endorsed reasons for use included the following: sleep disturbance (54.7%), pain (47.1%), and mood (42.6%). We found that moderate pain was associated with more than a twofold (odds ratio = 2.4 [95% confidence interval = 1.3-4.6], = 0.002) greater likelihood of self-reported cannabis use. Depressed mood and general health were not associated with cannabis use.
In a state that had early adoption of medical and recreational cannabis legislation, a high number of cancer survivors report cannabis use. Moderate or more severe pain was associated with an increased likelihood to use cannabis, while mood and general health were not associated. Oncologists should be aware of these trends and assess use of cannabis when managing long-term symptoms of cancer and its treatments.
在癌症患者中，使用大麻进行症状管理的情况越来越普遍。
我们试图描述（1）大麻使用的患病率和特征，（2）大麻使用的感知治疗益处，以及（3）在俄勒冈健康与科学大学奈特癌症研究所（由美国国立癌症研究所指定）接受治疗的患者代表性样本中，大麻使用与自我报告的疼痛、情绪和总体健康结果之间的关联。
我们开展了一项基于人群的横断面调查，该调查与其他11家由美国国立癌症研究所指定的癌症中心联合制定，并分发给符合条件的个体。该调查询问了大麻使用的特征、对治疗益处的感知、疼痛、情绪和总体健康情况。对回答进行了人群加权。我们使用逻辑回归，在控制相关社会人口统计学和临床特征的情况下，研究大麻使用与自我报告的疼痛、情绪和总体健康之间的关联。
我们的分析样本共纳入了523名个体。共有54%的人认可自癌症诊断以来的任何时间使用过大麻，42%的人认可在积极治疗期间使用过大麻。最常认可的使用原因包括：睡眠障碍（54.7%）、疼痛（47.1%）和情绪（42.6%）。我们发现中度疼痛与自我报告使用大麻的可能性高出两倍多（优势比 = 2.4 [95%置信区间 = 1.3 - 4.6]，P = 0.002）相关。情绪低落和总体健康状况与大麻使用无关。
在一个较早通过医用和娱乐用大麻立法的州，大量癌症幸存者报告使用过大麻。中度或更严重的疼痛与使用大麻的可能性增加相关，而情绪和总体健康状况则与之无关。肿瘤学家在管理癌症及其治疗的长期症状时应了解这些趋势并评估大麻的使用情况。
